Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 ± famitinib in advanced non-small cell lung cancer
CTR20202698Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Jan 2021; status: terminated.
02
Drugs
retlirafusp alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20202698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202698.